Glaxo's Shingles Vaccine 'Encouraging' But Shares Dip On Quarterly Lag [Investor's Business Daily]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Investors Business Daily
Related news 4/24/2018 Eli Lilly topped the Street's first-quarter estimates Tuesday on unexpected strength from two diabetes drugs and the early impact of... Merck's Keytruda Could Soon Be Worth $16 Billion As It Flies Past Bristol's Opdivo Premarket Trading: Futures Rise As Merck, CAT Get Upgrades Allergan Bows Out Of Shire Battle Against Takeda After Stock Slammed Novartis Stock Dips After Cosentyx Sales, Sandoz Generics Disappoint Why Dow Jones' Merck Looks Poised To Edge Out Bristol In Lung Cancer J&J Boosts Sales Forecast On Growing Demand For Cancer Drugs Premarket Trading: Blue Chips, Netflix Power Up; China Adds Tariffs Dow Hits Resistance At 50-Day As Apple Stock Moves Higher GlaxoSmithKline 's ( GSK ) potential blockbuster shingles vaccine had an "encouraging" start in the first quarter, Chief Executive Emma Walmsley said Wednesday, but Glaxo stock toppled on its broader revenue and profit lag. The vaccine, called Shingrix,
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Merck raises guidance as Keytruda sales jump 20% in Q1 [Seeking Alpha]Seeking Alpha
- Merck Raises Forecast as Sales of Its Cancer Immune Therapy Soar [BNN Bloomberg (Canada)]BNN Bloomberg
- Merck Announces First-Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- Merck raises 2024 profit forecast on strong cancer, HPV drugs sales [Reuters]Reuters
- Merck beats earnings expectations, raises outlook on strong Keytruda and vaccine sales [CNBC]CNBC
MRK
Earnings
- 4/25/24 - Beat
MRK
Sec Filings
- 4/25/24 - Form 8-K
- 4/11/24 - Form ARS
- 4/11/24 - Form DEFA14A
- MRK's page on the SEC website